Effects of benazepril and valsartan on erythropoietin levels in patients with essential hypertension / 南方医科大学学报
Journal of Southern Medical University
;
(12): 1761-1763, 2011.
Artículo
en Chino
| WPRIM
| ID: wpr-333819
ABSTRACT
<p><b>OBJECTIVE</b>To compare effects of valsartan and benazepril on erythropoietin (EPO) levels in essential hypertensive patients with normal renal function.</p><p><b>METHODS</b>Sixty essential hypertensive patients were randomly divided into valsartan group (n=30, valsartan 80 mg/day) and benazepril group (n=30, benazepril 10 mg/day). Plasma EPO and hemoglobin (Hb) levels were measured at the start of and at 4 and 8 weeks during the treatments.</p><p><b>RESULTS</b>EPO and Hb levels were all in normal range in the two groups. Valsartan decreased EPO levels from 14.179∓3.214 U/L (baseline) to 12.138∓2.926 U/L (P<0.05) and Hb levels from 144.32∓13.84 g/L (baseline) to 135.16∓14.78 U/L (P<0.05). Benazepril treatment did not resulted in any obvious changes in EPO or Hb levels (P>0.05).</p><p><b>CONCLUSION</b>Valsartan may lower EPO and Hb levels in patients with essential hypertension, while benazepril does not have such effects. The safety of valsartan in anemic hypertensive patients should be further investigated.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Tetrazoles
/
Valina
/
Benzazepinas
/
Sangre
/
Hemoglobinas
/
Eritropoyetina
/
Usos Terapéuticos
/
Quimioterapia
/
Valsartán
/
Hipertensión
Límite:
Adulto
/
Anciano
/
Aged80
/
Femenino
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Journal of Southern Medical University
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS